169 related articles for article (PubMed ID: 36246799)
1. Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report.
Li LJ; Zhang JY
World J Clin Cases; 2022 Oct; 10(28):10193-10200. PubMed ID: 36246799
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma.
Cai Q; Cai J; Fang Y; Young KH
Front Oncol; 2019; 9():386. PubMed ID: 31139570
[TBL] [Abstract][Full Text] [Related]
3. A Rare Case of Aggressive Disseminated Nasal-Type Epstein-Barr Virus-Positive Extranodal Natural Killer/T-Cell Lymphoma with Bone Marrow Involvement.
Yee AC; Karim FW; Giashuddin SM; Grutman G
Am J Case Rep; 2023 Jun; 24():e939286. PubMed ID: 37384825
[TBL] [Abstract][Full Text] [Related]
4. NK/T Cell Lymphoma: Updates in Therapy.
Suzuki R
Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
[TBL] [Abstract][Full Text] [Related]
5. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.
Han L; Liu F; Li R; Li Z; Chen X; Zhou Z; Zhang X; Hu T; Zhang Y; Young K; Sun S; Wen J; Zhang M
Oncol Lett; 2014 Oct; 8(4):1461-1469. PubMed ID: 25202350
[TBL] [Abstract][Full Text] [Related]
6. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
[TBL] [Abstract][Full Text] [Related]
7. New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma.
Yi W; Yang T; Lin S; Hao R; Yu J; Wang Y; Tong X
Cancer Manag Res; 2022; 14():401-407. PubMed ID: 35115837
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
9. Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy.
Nagato T; Komatsuda H; Hayashi R; Takahara M; Kishibe K; Yasuda S; Yajima Y; Kosaka A; Ohkuri T; Oikawa K; Harabuchi S; Kono M; Yamaki H; Wakisaka R; Hirata-Nozaki Y; Ohara K; Kumai T; Katada A; Hayashi T; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2023 Jul; 72(7):2087-2098. PubMed ID: 36811663
[TBL] [Abstract][Full Text] [Related]
10. [Extranodal NK/T-cell lymphoma].
Suzuki R
Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
13. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
Makita S; Tobinai K
Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
[TBL] [Abstract][Full Text] [Related]
15. Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells
Ando M; Ando J; Yamazaki S; Ishii M; Sakiyama Y; Harada S; Honda T; Yamaguchi T; Nojima M; Ohshima K; Nakauchi H; Komatsu N
Haematologica; 2020 Mar; 105(3):796-807. PubMed ID: 31296577
[TBL] [Abstract][Full Text] [Related]
16. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma.
Suzuki R
Semin Hematol; 2014 Jan; 51(1):42-51. PubMed ID: 24468315
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: A case report.
Asif S; Begemann M; Bennett J; Fatima R; Masood A; Raza S
Mol Clin Oncol; 2019 Mar; 10(3):397-400. PubMed ID: 30847181
[TBL] [Abstract][Full Text] [Related]
19. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
20. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
